Anti-Wolbachia drug discovery and development: safe macrofilaricides for onchocerciasis and lymphatic filariasis
about
Doxycycline plus ivermectin versus ivermectin alone for treatment of patients with onchocerciasisFinding Wolbachia in Filarial larvae and Culicidae Mosquitoes in Upper Egypt GovernorateWolbachia Endobacteria in Natural Populations of Culex pipiens of Iran and Its Phylogenetic CongruenceOpen Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and BeyondResearch for new drugs for elimination of onchocerciasis in AfricaComparison of Doxycycline, Minocycline, Doxycycline plus Albendazole and Albendazole Alone in Their Efficacy against Onchocerciasis in a Randomized, Open-Label, Pilot TrialPolyanhydride Nanoparticle Delivery Platform Dramatically Enhances Killing of Filarial WormsGenomic evidence for plant-parasitic nematodes as the earliest Wolbachia hostsA host as an ecosystem: Wolbachia coping with environmental constraints.Short-Course, High-Dose Rifampicin Achieves Wolbachia Depletion Predictive of Curative Outcomes in Preclinical Models of Lymphatic Filariasis and Onchocerciasis.Reciprocal Interactions between Nematodes and Their Microbial EnvironmentsWolbachia lipoproteins: abundance, localisation and serology of Wolbachia peptidoglycan associated lipoprotein and the Type IV Secretion System component, VirB6 from Brugia malayi and Aedes albopictus.Repurposing of approved drugs from the human pharmacopoeia to target Wolbachia endosymbionts of onchocerciasis and lymphatic filariasis.Potential involvement of Brugia malayi cysteine proteases in the maintenance of the endosymbiotic relationship with WolbachiaTherapeutic efficacy and macrofilaricidal activity of doxycycline for the treatment of river blindnessDevelopment and validation of a high-throughput anti-Wolbachia whole-cell screen: a route to macrofilaricidal drugs against onchocerciasis and lymphatic filariasis.Doxycycline Leads to Sterility and Enhanced Killing of Female Onchocerca volvulus Worms in an Area With Persistent Microfilaridermia After Repeated Ivermectin Treatment: A Randomized, Placebo-Controlled, Double-Blind TrialFit for purpose: do we have the right tools to sustain NTD elimination?Relationship between oral declaration on adherence to ivermectin treatment and parasitological indicators of onchocerciasis in an area of persistent transmission despite a decade of mass drug administration in CameroonEvidence of suppression of onchocerciasis transmission in the Venezuelan Amazonian focus.Minocycline as a re-purposed anti-Wolbachia macrofilaricide: superiority compared with doxycycline regimens in a murine infection model of human lymphatic filariasis.Onchocerciasis, an undiagnosed disease in Mozambique: identifying research opportunities.Modelling Neglected Tropical Diseases diagnostics: the sensitivity of skin snips for Onchocerca volvulus in near elimination and surveillance settings.Stage-specific Proteomes from Onchocerca ochengi, Sister Species of the Human River Blindness Parasite, Uncover Adaptations to a Nodular Lifestyle.Efficacy of three-week oxytetracycline or rifampin monotherapy compared with a combination regimen against the filarial nematode Onchocerca ochengiThe genome of Onchocerca volvulus, agent of river blindness.Genome-wide analysis of ivermectin response by Onchocerca volvulus reveals that genetic drift and soft selective sweeps contribute to loss of drug sensitivity.Identification and prioritization of novel anti-Wolbachia chemotypes from screening a 10,000-compound diversity library.Virtual screening of traditional Chinese medicine (TCM) database: identification of fragment-like lead molecules for filariasis target asparaginyl-tRNA synthetase.The case for vaccine development in the strategy to eradicate river blindness (onchocerciasis) from Africa.Albendazole and antibiotics synergize to deliver short-course anti-Wolbachia curative treatments in preclinical models of filariasis.Economic evaluations of lymphatic filariasis interventions: a systematic review and research needs.Identifying co-endemic areas for major filarial infections in sub-Saharan Africa: seeking synergies and preventing severe adverse events during mass drug administration campaigns.Combinations of registered drugs reduce treatment times required to deplete Wolbachia in the Litomosoides sigmodontis mouse model.Modeling Host-Microbiome Interactions in Caenorhabditis elegans.Mining Filarial Genomes for Diagnostic and Therapeutic Targets.Brugia malayi infection in ferrets - A small mammal model of lymphatic filariasis.Mansonellosis: current perspectivesQuinolone-fused cyclic sulfonamide as a novel benign antifilarial agentThe role of modern drug discovery in the fight against neglected and tropical diseases
P2860
Q24186468-42EB5EC4-D869-4D18-94DB-3495EACE8671Q26315219-4252A556-790C-4780-AFCF-C6DA73D4165DQ26315322-B97EDC40-A2EB-42C4-8BDE-0041C9CE37BCQ27826351-E566B02A-9168-43C9-A21F-624990C93F49Q28066402-70A0D18C-72E0-4236-ACD9-58D76B070901Q28468411-CE7275E0-9CC5-4863-AF5D-9EC64C877D80Q28550462-59D2A607-D878-476A-A644-B6A889F93D31Q28597686-E21E5093-2F94-428A-8B29-EBFA51B0F40CQ30364992-0A751DC9-00FA-43C4-ADC0-E1F16C3C96C0Q30377066-3104A659-0E60-41DA-BB1C-B976FF178114Q33607026-0FBA7ADA-CC28-4AF8-977B-B11893092B89Q34339870-FCB9E182-370A-4D61-859B-3FF4FBC520D5Q34454263-3AC943F9-3401-4F7F-869E-1A5576C611D4Q34705835-98950020-01DA-465F-ABCB-CAE001B399D2Q35207455-37C42805-EE3C-4A30-B3B0-A6359B6DBE95Q35297570-08A026C2-80E6-4C1A-A438-77409E30E0E9Q35898029-482BC220-30BB-4715-BA86-44ED668DC590Q36303972-3C5DB65A-3BE9-49D3-A7D1-A395DB7D5271Q36417053-891E39FC-21FA-44AE-93F1-D7E32EE2D2D6Q36507933-1C21B2DC-7F94-432B-88DE-DD59465ABE47Q36708214-A42E0A5E-7B99-4B5D-B7BA-23368CA0B0C7Q36749086-F05D1A1E-3C80-41F2-8596-31B9A8754729Q37006791-3A4CA52B-F9B5-4B66-8277-3B9A9D385171Q37153483-5B9BDEB0-4422-4873-9BC1-18FE59DBE97FQ37544726-1B2A50CD-FACA-4DAF-BAE0-B03FF9D7A93BQ37643713-F39FDDF2-8325-4546-85E1-005FDD7F6215Q38977668-E2A29508-CE3C-41EF-AAF8-800DAFF42815Q41678406-C48F042F-4D27-4C62-A38B-589681FFC8E4Q42214654-06A754CC-3692-4542-AD00-FD5E2EAAD46AQ43450951-FC63DFD0-AE72-428E-A343-349334A86551Q44288385-274CB583-B1B8-469F-A520-DE8139DDCB13Q47553077-A3043F87-D870-4D17-A830-C4811BA1D526Q48139837-DEC51E32-FA21-4FF5-88EA-E46ED41F9721Q48309955-DEA4AA3E-8284-4B7E-AD1D-DFDB2D6D6DA9Q49403382-9590704A-D3F4-4DB5-BDDF-244CAD2FCA62Q50068591-376A3873-B189-4FBA-BA3D-2BE47C53137BQ52619032-4A88881D-DD29-4657-BA24-E8AF3FE8784BQ56413671-55C9A289-613B-4DD8-8E21-4B87DE3548ADQ57169750-3268350A-ED53-4343-8766-59CC68AF0894Q58854103-3B8236B5-17EA-4292-9794-CD402D5D4DD8
P2860
Anti-Wolbachia drug discovery and development: safe macrofilaricides for onchocerciasis and lymphatic filariasis
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Anti-Wolbachia drug discovery ...... iasis and lymphatic filariasis
@ast
Anti-Wolbachia drug discovery ...... iasis and lymphatic filariasis
@en
Anti-Wolbachia drug discovery ...... iasis and lymphatic filariasis
@nl
type
label
Anti-Wolbachia drug discovery ...... iasis and lymphatic filariasis
@ast
Anti-Wolbachia drug discovery ...... iasis and lymphatic filariasis
@en
Anti-Wolbachia drug discovery ...... iasis and lymphatic filariasis
@nl
prefLabel
Anti-Wolbachia drug discovery ...... iasis and lymphatic filariasis
@ast
Anti-Wolbachia drug discovery ...... iasis and lymphatic filariasis
@en
Anti-Wolbachia drug discovery ...... iasis and lymphatic filariasis
@nl
P2093
P2860
P921
P3181
P1433
P1476
Anti-Wolbachia drug discovery ...... iasis and lymphatic filariasis
@en
P2093
Barton E Slatko
Simon Townson
Stephen A Ward
P2860
P304
P3181
P356
10.1017/S0031182013001108
P407
P5008
P577
2014-01-01T00:00:00Z